[144] AdvanSix Inc. SEC Filing

Rhea-AI Filing Summary

Sage Therapeutics, Inc. (SAGE) filed a Post-Effective Amendment to 15 previously effective Form S-8 registrations to deregister all remaining, unissued shares that had been reserved for employee equity plans. The action follows the 31 Jul 2025 closing of the merger whereby Supernus Pharmaceuticals, Inc. acquired Sage through its subsidiary Saphire, Inc., leaving Sage a wholly owned subsidiary of Supernus.

The affected registrations covered roughly 35 million shares across the 2011 Stock Option & Grant Plan, the 2014 Stock Option & Incentive Plan, multiple ESPPs, the 2016 and 2024 inducement/equity incentive plans, and related amendments. Because Sage’s securities offerings have ceased, the company is fulfilling its undertaking under Rule 415 to remove from registration any securities that remain unsold at termination of the offering. No additional securities will be issued under the listed plans, and the filings are amended solely to reflect this deregistration.

Insights

Corporate Actions Analyst

TL;DR: Housekeeping filing; all unused S-8 shares removed after Supernus acquisition—neutral to investors.

The amendment is a routine step completed after the 31 July 2025 merger closed. Once Sage became a wholly owned subsidiary of Supernus, its public equity programs ceased to exist. Consequently, the company must legally deregister any shares that will never be issued. This does not alter deal economics already set in the merger agreement and has no incremental cash impact on Supernus or former Sage shareholders. It simply cleans the SEC register and eliminates future share-based issuance capacity at the Sage level. Overall impact on valuation, liquidity, or capital structure is negligible.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Merrill Lynch 225 Liberty St Floor 37 New York NY 10281	571	11522.78	26812687	08/01/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	02/28/2025	Vesting of restricted stock unit award	AdvanSix Inc.			571	02/28/2025	Granted as part of issuer equity compensation plan

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Achilles Kintiroglou 300 KIMBALL DRIVE SUITE 101 PARSIPPANY NJ 07054	Common Stock	07/02/2025	571	14189.35
Achilles Kintiroglou 300 KIMBALL DRIVE SUITE 101 PARSIPPANY NJ 07054	Common Stock	06/02/2025	571	13504.15

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

Why did Sage Therapeutics file this S-8 POS amendment?

To deregister all shares that were reserved under its equity plans but remain unissued after the 31 Jul 2025 merger with Supernus.

How many shares are being deregistered by SAGE?

Approximately 35 million common shares across 15 separate S-8 registration statements.

What happened to Sage Therapeutics on 31 July 2025?

It merged with a Supernus Pharmaceuticals subsidiary and now operates as a wholly owned subsidiary of Supernus.

Will Sage issue any more shares under its employee equity plans?

No. All listed plans are terminated, and no additional shares will be issued.

Does this filing affect Supernus (SUPN) shareholders?

The amendment is administrative and has no direct financial impact on Supernus; merger terms remain unchanged.